These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 8788432)
21. Potentiation of delta 9-tetrahydrocannabinol-induced analgesia by morphine in mice: involvement of mu- and kappa-opioid receptors. Reche I; Fuentes JA; Ruiz-Gayo M Eur J Pharmacol; 1996 Dec; 318(1):11-6. PubMed ID: 9007506 [TBL] [Abstract][Full Text] [Related]
22. Interaction of beta-funaltrexamine with [3H]cycloFOXY binding in rat brain: further evidence that beta-FNA alkylates the opioid receptor complex. Rothman RB; Bykov V; Mahboubi A; Long JB; Jiang Q; Porreca F; de Costa BR; Jacobson AE; Rice KC; Holaday JW Synapse; 1991 Jun; 8(2):86-99. PubMed ID: 1652797 [TBL] [Abstract][Full Text] [Related]
23. Displacement of opioid receptor binding ligands from the rat brain by N3-(2',5'-dimethoxyphenacyl) arabinofuranosyluracil. Shimizu T; Kimura T; Funahashi T; Watanabe K; Ho IK; Yamamoto I Res Commun Mol Pathol Pharmacol; 2005; 117-118():105-13. PubMed ID: 18426082 [TBL] [Abstract][Full Text] [Related]
24. Antinociceptive properties of two alkylating derivatives of morphinone: 14 beta-(thioglycolamido)-7,8-dihydromorphinone (TAMO) and 14 beta-(bromoacetamido)-7,8-dihydromorphinone (H2BAMO). Jiang Q; Seyed-Mozaffari A; Archer S; Bidlack JM J Pharmacol Exp Ther; 1992 Aug; 262(2):526-31. PubMed ID: 1380079 [TBL] [Abstract][Full Text] [Related]
25. Antinociceptive evaluation of 14 beta-(bromoacetamido)-7,8-dihydro- N(cyclopropylmethyl)-normorphinone in mice. Jiang Q; Seyed-Mozaffari A; Archer S; Bidlack JM Eur J Pharmacol; 1993 Aug; 240(2-3):201-6. PubMed ID: 7694857 [TBL] [Abstract][Full Text] [Related]
27. Effect of a 6-cyano substituent in 14-oxygenated N-methylmorphinans on opioid receptor binding and antinociceptive potency. Spetea M; Greiner E; Aceto MD; Harris LS; Coop A; Schmidhammer H J Med Chem; 2005 Jul; 48(15):5052-5. PubMed ID: 16033285 [TBL] [Abstract][Full Text] [Related]
28. Evaluation of delta receptor mediation of supraspinal opioid analgesia by in vivo protection against the beta-funaltrexamine antagonist effect. Sánchez-Blázquez P; Garzón J Eur J Pharmacol; 1989 Jan; 159(1):9-23. PubMed ID: 2565240 [TBL] [Abstract][Full Text] [Related]
29. Selective antagonism by naloxonazine of antinociception by Tyr-D-Arg-Phe-beta-Ala, a novel dermorphin analogue with high affinity at mu-opioid receptors. Sakurada S; Takeda S; Sato T; Hayashi T; Yuki M; Kutsuwa M; Tan-No K; Sakurada C; Kisara K; Sakurada T Eur J Pharmacol; 2000 Apr; 395(2):107-12. PubMed ID: 10794815 [TBL] [Abstract][Full Text] [Related]
30. Nociceptin/orphanin FQ blocks the antinociception induced by mu, kappa and delta opioid agonists on the cold water tail-flick test. Chen X; Geller EB; Adler MW Eur J Pharmacol; 2007 Feb; 557(1):32-6. PubMed ID: 17173891 [TBL] [Abstract][Full Text] [Related]
31. Blockade of mu-opioid receptor-mediated G-protein activation and antinociception by TRK-820 in mice. Mizoguchi H; Hung KC; Leitermann R; Narita M; Nagase H; Suzuki T; Tseng LF Eur J Pharmacol; 2003 Feb; 461(1):35-9. PubMed ID: 12568913 [TBL] [Abstract][Full Text] [Related]
32. Streptozotocin-induced diabetes selectively alters the potency of analgesia produced by mu-opioid agonists, but not by delta- and kappa-opioid agonists. Kamei J; Ohhashi Y; Aoki T; Kawasima N; Kasuya Y Brain Res; 1992 Feb; 571(2):199-203. PubMed ID: 1319265 [TBL] [Abstract][Full Text] [Related]
33. Gonadal hormone modulation of mu, kappa, and delta opioid antinociception in male and female rats. Stoffel EC; Ulibarri CM; Folk JE; Rice KC; Craft RM J Pain; 2005 Apr; 6(4):261-74. PubMed ID: 15820914 [TBL] [Abstract][Full Text] [Related]
34. Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors. Yamada H; Shimoyama N; Sora I; Uhl GR; Fukuda Y; Moriya H; Shimoyama M Brain Res; 2006 Apr; 1083(1):61-9. PubMed ID: 16530171 [TBL] [Abstract][Full Text] [Related]
35. 5 beta-Methyl-14 beta-(p-nitrocinnamoylamino)-7,8-dihydromorphinone: a long-lasting mu-opioid receptor antagonist devoid of agonist properties. Jiang Q; Sebastian A; Archer S; Bidlack JM Eur J Pharmacol; 1993 Jan; 230(1):129-30. PubMed ID: 7679076 [TBL] [Abstract][Full Text] [Related]
36. Differential antagonism of opioid delta antinociception by [D-Ala2,Leu5,Cys6]enkephalin and naltrindole 5'-isothiocyanate: evidence for delta receptor subtypes. Jiang Q; Takemori AE; Sultana M; Portoghese PS; Bowen WD; Mosberg HI; Porreca F J Pharmacol Exp Ther; 1991 Jun; 257(3):1069-75. PubMed ID: 1646319 [TBL] [Abstract][Full Text] [Related]
37. Potency differences for D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 as an antagonist of peptide and alkaloid micro-agonists in an antinociception assay. Sterious SN; Walker EA J Pharmacol Exp Ther; 2003 Jan; 304(1):301-9. PubMed ID: 12490605 [TBL] [Abstract][Full Text] [Related]
39. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine. Broadbear JH; Sumpter TL; Burke TF; Husbands SM; Lewis JW; Woods JH; Traynor JR J Pharmacol Exp Ther; 2000 Sep; 294(3):933-40. PubMed ID: 10945843 [TBL] [Abstract][Full Text] [Related]